176 related articles for article (PubMed ID: 18395459)
21. Differential morphology and composition of inclusions in the R6/2 mouse and PC12 cell models of Huntington's disease.
Wanderer J; Morton AJ
Histochem Cell Biol; 2007 May; 127(5):473-84. PubMed ID: 17285342
[TBL] [Abstract][Full Text] [Related]
22. Prevention of Huntington's Disease-Like Behavioral Deficits in R6/1 Mouse by Tolfenamic Acid Is Associated with Decreases in Mutant Huntingtin and Oxidative Stress.
Liu P; Li Y; Yang W; Liu D; Ji X; Chi T; Guo Z; Li L; Zou L
Oxid Med Cell Longev; 2019; 2019():4032428. PubMed ID: 31049134
[TBL] [Abstract][Full Text] [Related]
23. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease.
Mievis S; Blum D; Ledent C
Neurobiol Dis; 2011 Feb; 41(2):570-6. PubMed ID: 21062644
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice.
Stack EC; Dedeoglu A; Smith KM; Cormier K; Kubilus JK; Bogdanov M; Matson WR; Yang L; Jenkins BG; Luthi-Carter R; Kowall NW; Hersch SM; Beal MF; Ferrante RJ
J Neurosci; 2007 Nov; 27(47):12908-15. PubMed ID: 18032664
[TBL] [Abstract][Full Text] [Related]
25. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
[TBL] [Abstract][Full Text] [Related]
26. Modulation of nucleosome dynamics in Huntington's disease.
Stack EC; Del Signore SJ; Luthi-Carter R; Soh BY; Goldstein DR; Matson S; Goodrich S; Markey AL; Cormier K; Hagerty SW; Smith K; Ryu H; Ferrante RJ
Hum Mol Genet; 2007 May; 16(10):1164-75. PubMed ID: 17403718
[TBL] [Abstract][Full Text] [Related]
27. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease.
Gardian G; Browne SE; Choi DK; Klivenyi P; Gregorio J; Kubilus JK; Ryu H; Langley B; Ratan RR; Ferrante RJ; Beal MF
J Biol Chem; 2005 Jan; 280(1):556-63. PubMed ID: 15494404
[TBL] [Abstract][Full Text] [Related]
28. Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.
Aggarwal M; Duan W; Hou Z; Rakesh N; Peng Q; Ross CA; Miller MI; Mori S; Zhang J
Neuroimage; 2012 May; 60(4):2086-95. PubMed ID: 22342677
[TBL] [Abstract][Full Text] [Related]
29. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
[TBL] [Abstract][Full Text] [Related]
30. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
[TBL] [Abstract][Full Text] [Related]
31. Preconditioning mesenchymal stem cells with the mood stabilizers lithium and valproic acid enhances therapeutic efficacy in a mouse model of Huntington's disease.
Linares GR; Chiu CT; Scheuing L; Leng Y; Liao HM; Maric D; Chuang DM
Exp Neurol; 2016 Jul; 281():81-92. PubMed ID: 27085395
[TBL] [Abstract][Full Text] [Related]
32. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
[TBL] [Abstract][Full Text] [Related]
33. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease.
Keene CD; Rodrigues CM; Eich T; Chhabra MS; Steer CJ; Low WC
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10671-6. PubMed ID: 12149470
[TBL] [Abstract][Full Text] [Related]
34. 2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.
Wu B; Jiang M; Peng Q; Li G; Hou Z; Milne GL; Mori S; Alonso R; Geisler JG; Duan W
Exp Neurol; 2017 Jul; 293():83-90. PubMed ID: 28359739
[TBL] [Abstract][Full Text] [Related]
35. Lipoic acid improves survival in transgenic mouse models of Huntington's disease.
Andreassen OA; Ferrante RJ; Dedeoglu A; Beal MF
Neuroreport; 2001 Oct; 12(15):3371-3. PubMed ID: 11711888
[TBL] [Abstract][Full Text] [Related]
36. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
37. Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington's disease.
Stepanova P; Kumar D; Cavonius K; Korpikoski J; Sirjala J; Lindholm D; Voutilainen MH
Sci Rep; 2023 Feb; 13(1):2953. PubMed ID: 36807563
[TBL] [Abstract][Full Text] [Related]
38. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
Kumar A; Kneynsberg A; Tucholski J; Perry G; van Groen T; Detloff PJ; Lesort M
Exp Neurol; 2012 Sep; 237(1):78-89. PubMed ID: 22698685
[TBL] [Abstract][Full Text] [Related]
39. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
40. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease.
Chiu CT; Liu G; Leeds P; Chuang DM
Neuropsychopharmacology; 2011 Nov; 36(12):2406-21. PubMed ID: 21796107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
